172 related articles for article (PubMed ID: 36926453)
1. Rational Drug Design of Targeted and Enzyme-Cleavable Vitamin E Analogs as a Neoadjuvant to Chemotherapy:
Pandurangi RS; Cseh O; Luchman HA; Ma CX; Senadheera SN; Forrest ML
ACS Pharmacol Transl Sci; 2023 Mar; 6(3):372-386. PubMed ID: 36926453
[TBL] [Abstract][Full Text] [Related]
2. A Priori Activation of Apoptosis Pathways of Tumor (AAAPT) technology: Development of targeted apoptosis initiators for cancer treatment.
Pandurangi RS; Tomasetti M; Verapazham ST; Paulmurugan R; Ma C; Rajput S; Anjanappa M; Nakshatri H
PLoS One; 2021; 16(2):e0225869. PubMed ID: 33556062
[TBL] [Abstract][Full Text] [Related]
3. Restoration of the Lost Human Beta Defensin (hBD-1) in Cancer as a Strategy to Improve the Efficacy of Chemotherapy.
Pandurangi RS; Sekar TV; Paulmurugan R
bioRxiv; 2023 Apr; ():. PubMed ID: 37066380
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin sensitizes cancer cells to Smac mimetic via synergistic activation of the CYLD/RIPK1/FADD/caspase-8-dependent apoptosis.
Yang C; Ran Q; Zhou Y; Liu S; Zhao C; Yu X; Zhu F; Ji Y; Du Q; Yang T; Zhang W; He S
Apoptosis; 2020 Jun; 25(5-6):441-455. PubMed ID: 32418059
[TBL] [Abstract][Full Text] [Related]
5. [10]-Gingerol improves doxorubicin anticancer activity and decreases its side effects in triple negative breast cancer models.
Baptista Moreno Martin AC; Tomasin R; Luna-Dulcey L; Graminha AE; Araújo Naves M; Teles RHG; da Silva VD; da Silva JA; Vieira PC; Annabi B; Cominetti MR
Cell Oncol (Dordr); 2020 Oct; 43(5):915-929. PubMed ID: 32761561
[TBL] [Abstract][Full Text] [Related]
6. Comparative study of cathepsin B-cleavable linkers for the optimal design of cathepsin B-specific doxorubicin prodrug nanoparticles for targeted cancer therapy.
Shim N; Jeon SI; Yang S; Park JY; Jo M; Kim J; Choi J; Yun WS; Kim J; Lee Y; Shim MK; Kim Y; Kim K
Biomaterials; 2022 Oct; 289():121806. PubMed ID: 36156411
[TBL] [Abstract][Full Text] [Related]
7. Oridonin synergistically enhances the anti-tumor efficacy of doxorubicin against aggressive breast cancer via pro-apoptotic and anti-angiogenic effects.
Li J; Wu Y; Wang D; Zou L; Fu C; Zhang J; Leung GP
Pharmacol Res; 2019 Aug; 146():104313. PubMed ID: 31202781
[TBL] [Abstract][Full Text] [Related]
8. Combination treatment with doxorubicin and gamitrinib synergistically augments anticancer activity through enhanced activation of Bim.
Park HK; Lee JE; Lim J; Jo DE; Park SA; Suh PG; Kang BH
BMC Cancer; 2014 Jun; 14():431. PubMed ID: 24927938
[TBL] [Abstract][Full Text] [Related]
9. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
[TBL] [Abstract][Full Text] [Related]
10. PEGylated liposomal doxorubicin targeted to α5β1-expressing MDA-MB-231 breast cancer cells.
Shroff K; Kokkoli E
Langmuir; 2012 Mar; 28(10):4729-36. PubMed ID: 22268611
[TBL] [Abstract][Full Text] [Related]
11. Liposomes co-encapsulating doxorubicin and glucoevatromonoside derivative induce synergic cytotoxic response against breast cancer cell lines.
Novais MVM; Gomes ER; Miranda MC; Silva JO; Gomes DA; Braga FC; Pádua RM; Oliveira MC
Biomed Pharmacother; 2021 Apr; 136():111123. PubMed ID: 33486211
[TBL] [Abstract][Full Text] [Related]
12. Pivarubicin Is More Effective Than Doxorubicin Against Triple-Negative Breast Cancer In Vivo.
Lothstein L; Soberman J; Parke D; Gandhi J; Sweatman T; Seagroves T
Oncol Res; 2020 Dec; 28(5):451-465. PubMed ID: 32430093
[TBL] [Abstract][Full Text] [Related]
13. Nodal expression in triple-negative breast cancer: Cellular effects of its inhibition following doxorubicin treatment.
Bodenstine TM; Chandler GS; Reed DW; Margaryan NV; Gilgur A; Atkinson J; Ahmed N; Hyser M; Seftor EA; Strizzi L; Hendrix MJ
Cell Cycle; 2016 May; 15(9):1295-302. PubMed ID: 27007464
[TBL] [Abstract][Full Text] [Related]
14. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
15. Induction of P-glycoprotein expression by dandelion in tumor and heart tissues: Impact on the anti-tumor activity and cardiotoxicity of doxorubicin.
Qu J; Ke F; Yang X; Wang Y; Xu H; Li Q; Bi K
Phytomedicine; 2022 Sep; 104():154275. PubMed ID: 35760022
[TBL] [Abstract][Full Text] [Related]
16. GATA4-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo: establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes.
Karhu ST; Kinnunen SM; Tölli M; Välimäki MJ; Szabó Z; Talman V; Ruskoaho H
Arch Toxicol; 2020 Jun; 94(6):2113-2130. PubMed ID: 32185414
[TBL] [Abstract][Full Text] [Related]
17. Co-delivery of Doxorubicin and Curcumin with Polypeptide Nanocarrier for Synergistic Lymphoma Therapy.
Guo W; Song Y; Song W; Liu Y; Liu Z; Zhang D; Tang Z; Bai O
Sci Rep; 2020 May; 10(1):7832. PubMed ID: 32398729
[TBL] [Abstract][Full Text] [Related]
18. Enhanced metastasis suppression by targeting TRAIL receptor 2 in a murine model of triple-negative breast cancer.
Malin D; Chen F; Schiller C; Koblinski J; Cryns VL
Clin Cancer Res; 2011 Aug; 17(15):5005-15. PubMed ID: 21653692
[TBL] [Abstract][Full Text] [Related]
19. Targeted delivery of vitamin D3-loaded nanoparticles to C6 glioma cell line increased resistance to doxorubicin, epirubicin, and docetaxel in vitro.
Maleklou N; Allameh A; Kazemi B
In Vitro Cell Dev Biol Anim; 2016 Dec; 52(10):989-1000. PubMed ID: 27503515
[TBL] [Abstract][Full Text] [Related]
20. Anticancer effect and safety of doxorubicin and nutraceutical sulforaphane liposomal formulation in triple-negative breast cancer (TNBC) animal model.
Pogorzelska A; Mazur M; Świtalska M; Wietrzyk J; Sigorski D; Fronczyk K; Wiktorska K
Biomed Pharmacother; 2023 May; 161():114490. PubMed ID: 36931031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
